Skip to main content
Download PDF

Modern peptide biomarkers and echocardiography in cardiac healthy haemodialysis patients

BMC Nephrology volume 18, Article number: 175 (2017) Cite this article

Abstract

Background

In this prospective study, we aimed to assess the haemodynamic changes before and after haemodialysis (HD) in cardiac healthy subjects on chronic HD by imaging methods and endocrine markers of fluid balance.

Methods

Mid-regional pro-atrial natriuretic peptide (MR-proANP), N-terminal prohormone of brain natriuretic peptide (NT-proBNP), vasopressin (AVP) and copeptin (CT-proAVP), metanephrines and normetanephrines, renin and aldosterone, standard transthoracic echocardiography and diameter of vena cava inferior (VCID) were performed in 20 patients with end stage renal disease (CKD5D) before and after HD and were stratified in residual excretion (RE, less or more 0.5 l) and ultrafiltration rate (UF, less or more 2 l).

Results

Copeptin was significantly higher in patients before HD. Copeptin was inversely correlated with haemodialysis treatment adequacy (KT/v), RE and UF, but was not significantly influenced by age, gender and body mass index (BMI). MR-proANP was significantly reduced by haemodialysis by 27% and was inversely correlated with KT/v, but there was a significant influence by UF, RE, age, gender and BMI. NT-proBNP was significantly higher in patients before HD and was not influenced by RE and UF. Renin, aldosterone, metanephrines and normetanephrines did not demonstrate significant differences. Echocardiographic parameters and VCID were significantly correlated with RE, UF and copeptin.

Conclusion

Modern biomarkers will provide cardiovascular risk assessment, but elimination (UF), RE and other factors may influence the serum concentrations, e.g. in patients with renal impairment. The interpretation will be limited by altered reference ranges, and will be restricted to individual courses combined with clinical and echocardiographic data.

Peer Review reports

Background

Cardiovascular mortality in haemodialysis (HD) patients (CKD5D) is tenfold higher than in the normal population [1]. In patients with chronic kidney disease (CKD), excessive volume overload and arterial hypertension evoke characteristic morphological and functional cardiac changes – the chronic reno-cardiac syndrome type 4 (CRS) with left ventricular remodelling, dilatation of the left ventricle and the development of left ventricular hypertrophy [2,3,4]. Consequently, these patients are predisposed for the development of cardiac arrhythmias, uremic cardiomyopathy - a hybrid of hypertrophic and dilative cardiomyopathy - and finally left and right ventricular heart ailure [5,6,7]. Reliable serum biomarkers for prevention or monitoring of CRS are necessary in this high risk population in which morphological diagnostic is limited because of adverse effects of contrast media, e. g. contrast media nephropathy or nephrogenic fibrosis [8]. However, residual renal excretion and/or elimination by HD might have a significant influence on serum concentrations of these markers.

In the present study, we aimed to assess the influence of volume balance, residual kidney excretion, and elimination by HD. Therefore we measured novel biomarkers in cardiac healthy patients with CKD5D, e.g. copeptin [9,10,11,12,13,14,15,16], MR-proANP [17, 18], NT-proBNP [19,20,21,22,23,24,25] and non-invasive ultrasound parameters, i.e. oscillation of the diameter of the vena cava inferior and echocardiographic parameters, before and after HD.

Methods

Twenty cardiac healthy patients (male n = 10, female n = 10; glomerulonephritis n = 8, obstructive nephropathy n = 4, polycystic kidney disease n = 1, diabetes mellitus n = 1, unknown = 6) with a median age of 48 years (mean 48; SD 9; range 29 to 62) and CKD5D (median time on HD 29 months; range 3 to 102) were included in the prospective study at our outpatient haemodialysis care unit. All clinical investigations were performed at the midweek HD session.

Exclusion criteria were severe malignancy, arterial hypertension, acute myocardial infarction, heart failure, structural heart disease, ascites, pericardial or pleural effusion, complex arrhythmias, and moderate or severe valvular heart disease, pacemakers or other devices. None of the patients suffered from peripheral artery disease, stroke or diabetes mellitus, except only one patient with diabetes mellitus type 1 with kidney and pancreas transplantation and with exclusion of ischemic heart disease by invasive diagnostics before renal transplantation. In this single patient, transplant function of the kidney was lost by histologically confirmed chronic glomerulopathy after transplantation without any signs of diabetes mellitus. However, the endocrine pancreas function still remained until these days with sufficient blood glucose control (HbA1c < 5.5%).

The study protocol was approved by the institutional review board, Medical Faculty of the University of Leipzig (No. 089-10-19,042,010), and informed consent was obtained from all patients.

Haemodialysis prescriptions

Haemodialysis was performed three times per week with a mean time of 4.85 h (five hours n = 17; four hours n = 3), proven arterial fistula blood flow >800 ml/min, machine blood flow 300 ml/min, dialysate flow 500 ml/min, dialysate concentrations SW 285A (Na+ 138, K+ 3) and SW 393A (Na+ 138, K+ 4) (Braun, Germany), high flux membrane/dialyzer Polyflux 170H (Nikkiso, Japan), and haemodialysis machine DBB05 (Nikkiso, Japan). All patients had native fistulas. The cut off of the ultrafiltration rate was set by 2000 ml by the median of all patients of the employed session for the dichotomous variable “UF 2000 ml” (median 2000 ml, min 0 ml, max 5000 ml, mean 2055 ml).

Biochemistry

Haemoglobin (Hb), haematocrit (Hk), sodium, potassium, phosphate, creatinine, osmolality, albumine, vasopressin (AVP), aldosterone, renin, metanephrine, normetanephrine, MR-proANP, and copeptin [26] have been obtained by serum and plasma samples (EDTA, citrate, and heparin) before and after haemodialysis. Due to intradialytic elimination, NT-proBNP was solely measured before haemodialysis [27]. Additionally, KT/v was calculated using the Daugirdas formula [28, 29].

Echocardiography

In all patients standardised transthoracic echocardiography was performed by experienced cardiologists according to national and international recommendations before (after suitable rest of 20 min for each patient) and approximately 20 min after haemodialysis [30]. Echocardiographic investigations were performed with Vivid 7 or Vivid E9 (GE Healthcare, Frankfurt, Germany) and all parameters were analysed offline using the EchoPac-Software (GE Healthcare, Frankfurt, Germany).

Left ventricular (LV) systolic function was assessed by determining LV ejection fraction due to biplane LV volume analysis using the modified Simpson’s rule [31]. Left ventricular diastolic function was assessed by the following echocardiographic parameters. The early-diastolic (Emax) and late-diastolic (Amax) maximum velocity of the mitral valve inflow were assessed by pulsed-wave Doppler measurements in the apical long axis view. The sample volume was positioned 1-2 cm above the mitral ring at the junction of the mitral leaflets to the chord strands and inappropriate Doppler angles were avoided. Both peak velocities permit the calculation of the E/A-ratio. In addition, the deceleration time (EDT) describing the duration from E peak to the end of the E-wave.

The left ventricular end-diastolic pressure was assessed by the determination of E/E’-ratio. E’ describes the tissue velocity of the motion of a specific myocardial segment during diastole and was assessed by tissue Doppler measurements. The sample volume of the pulsed-wave tissue Doppler was positioned at the basal inferoseptal and basal lateral segment in the apical 4-chamber view to obtain E’-inferoseptal and E’-lateral, respectively. Thus, the E/E’-inferoseptal-ratio and E/E’-lateral-ratio could be determined [32].

The diameter of the vena cava inferior (VCID) was assessed in a subcostal short axis view where the vena cava inferior enters the right atrium. Three different diameters were determined via M-Mode during expiration of the patient to obtain the median of the VCID.

The echocardiographic parameters were correlated with the ultrafiltration rate (UR) and the residual excretion (RE).

Statistical methods

Non-parametric tests to compare group values (Wilcoxon-test, Friedman test, and Mann-Whitney-U-test) and bivariate correlation analysis (Spearman test, r regression coefficient) were performed as indicated. Statistical significance for all tests was set at a level of p < 0.05. Statistical analysis was done using the SPSS version 21.0 software package (SPSS Inc., Chicago, Illinois, USA). If not indicated otherwise, data are given as median values with range (minimum to maximum), or mean and standard deviation (± SD).

Results

Pre- and post-HD sampling, ultrafiltration rate, and residual urinary excretion rate – Influence on serum risk markers

Pre- and post-HD sampling was performed in our study and biochemistry parameters were determined before and after HD as shown in Table 1.

Table 1 Biochemistry parameters before and after haemodialysis (HD)
Full size table

In patients with an ultrafiltration rate ≥ 2000 ml aldosterone post-HD was significantly higher as in patients with an ultrafiltration rate < 2000 ml (Additional file 1: Table S1). In patients with a residual urinary excretion rate < 500 ml normetanephrine pre-HD was significantly lower as in patients with a rate > 500 ml. Copeptin pre- and post-HD was significantly higher in patients with an urinary excretion rate < 500 ml (Additional file 1: Table S2).

AVP and copeptin in regard to UF, RE, age, gender, BMI, and others

AVP was in normal range before HD and decreased after HD significantly by 27% (Fig. 1a). Only the percental reduction of copeptin (and not of AVP) was significantly correlated with the percental reduction of the body weight after HD (Spearman test in bivariate correlation analysis, p = 0.028, r = −0.503). In patients with an UF > 2000 ml, serum AVP levels were significantly higher (before HD: median 8.9 ng/l (4.4 - 9.4 ng/l); after HD median 6.9 ng/l (2.9 - 9.1 ng/l) than in patients with an UF < 2000 ml (before HD median 5.1 ng/l (1 - 7.7 ng/l; after HD median 2.7 ng/l (1 - 6.1 ng/l); p < 0.05). There was a trend in higher AVP levels in patients with a RE ≥ 500 ml (Additional file 1: Table S2). No influence of gender, age, or BMI was found. Copeptin levels were 11 fold higher in patients with HD as in the normal population (median 159 pmol/l, 14 - 291 pmol/l, normal median 4.2 pmol/l, 1 - 14 pmol/l [26] and there was a significant reduction of 54% by HD (Fig. 1b). Copeptin levels were significantly higher in patients with an UF ≥ 2000 before HD (median 207 pmol/l, 59 - 291 pmol/l, p < 0.05) and after HD (median 110 pmol/, 27 - 132 pmol/l, p < 0.01) than in patients with an UF < 2000 (median before HD 90 pmol/l, 14 - 196 pmol/l; median after HD 29 pmol/l, 8 - 75 pmol/l). After HD there was in both groups a significant reduction of copeptin and copeptin was significantly correlated with UF (Fig. 2A). Copeptin values were also correlated with the body weight. Thus, in case of increased body weight loss - in case of higher UF - during HD higher copeptin values were obtained (Fig. 2B). Significantly higher copeptin values were revealed in the group with RE < 500 ml (n = 9), either pre-HD (Median 193 pmol/l; 59 - 291 pmol/l) or post-HD (Median 106 pmol/l; 27 - 132 pmol/l) in comparison to the study group with RE ≥ 500 ml (n = 11, median before HD 95 pmol/l, 14 - 218 pmol/l; median after HD 39, 8 - 114 pmol/l). In addition, the statistical analysis showed a negative correlation between copeptin and RE (data not shown). Interestingly, older, male and obese patients tended to higher copeptin concentrations. The relative reduction of copeptin during HD significantly correlated inversely with the Kt/V ratio and the urea reduction indicating that copeptin might be eliminated by HD.

Fig. 1
figure 1

a AVP concentration before and after haemodialysis (HD). b Copeptin concentration before and after haemodialysis (HD)

Full size image
Fig. 2
figure 2

a Copeptin concentration before (a) and after (b) haemodialysis (HD) depending on ultrafiltration rate (UF). b Copeptin concentration before (a) and after (b) haemodialysis (HD) depending on patient residual excretion (RE)

Full size image

MR-proANP and NT-proBNP before and after HD

In parallel to AVP and copeptin, MR-proANP was significantly reduced about 26.8% after HD (median before HD 814 pmol/l (285 - 2908 pmol/l), median after HD 665 pmol/l (222 - 2144 pmol/l). Similarly to copeptin, all MR-proANP values were clearly above the normal range as described in the literature in non HD patients. Before HD, MR-proANP values were up to ten fold higher as in the normal population and after HD MR-proANP was still up to eight fold above the normal range in non HD patients (46.1 to 85.2 pmol/l). The percental reduction of MR-proANP was not significantly correlated with the percental reduction of the body weight after HD (Spearman test in bivariate correlation analysis, p = 0.9, r = −0.029). However, there was no significant difference relating to UF, RE, age, gender and BMI. In analogy to copeptin or MR-proANP, the NT-proBNP concentration (median 3020 ng/l, 522 - 72,312 ng/l) was about 18 fold elevated in comparison to the normal range (<169 ng/l).

Renin

There was an increase of renin after HD in 13 patients and a decrease of renin in seven patients after HD. In addition, there was a positive correlation of renin to UF after HD showing that a higher UR rate led to higher renin values after HD (r = 0.5 and p < 0.05). The percental reduction of renin was significantly correlated with the percental reduction of the body weight after HD (Spearman test in bivariate correlation analysis, p = 0.046, r = −0.452). Other significant correlations between renin and e.g. RE, age, BMI, blood pressure, antihypertensive drugs or remaining biochemistry parameters as proANP, proBNP, copeptin, AVP, aldosterone, meta- and normetanephrines could not be revealed (data not shown).

According to the different renin reaction patterns, patients with renin decrease (n = 7) and with renin increase (n = 13) after HD showed both significant differences for renin. A comparison of parameters depending from post-HD renin decrease or renin increase is shown in Additional file 1: Table S3.

Aldosterone

An inverse correlation between aldosterone and proANP was detected (r = −0.6, p < 0.01). This was similar to proBNP showing a significantly negative correlation to aldosterone (r = −0.5, p < 0.05). The percental reduction of aldosterone was significantly correlated with the percental reduction of the body weight after HD (Spearman test in bivariate correlation analysis, p = 0.00035, r = −0.790). Other significant correlations (e.g. age, BMI, gender, blood pressure, antihypertensive drugs or remaining biochemistry parameters) could not be revealed.

Similarly to renin, different aldosterone reaction patterns could be detected: patients with aldosterone decrease (n = 15) and with aldosterone increase (n = 5) after HD showed both significant differences for aldosterone. A comparison of parameters depending on post-HD aldosterone decrease (e. g. systolic blood pressure 2 h after the begin of HD) or aldosterone increase (e. g. haemoglobin, haematocrit, metanephrines) is shown in Additional file 1: Table S4.

Metanephrines and normetanephrines

Pre-HD metanephrine values were generally above the normal range (<90 ng/l) for metanephrines and there was a significant decrease after HD (Fig. 3a).

Fig. 3
figure 3

a Metanephrine concentration before and after haemodialysis (HD). b Normetanephrine concentration before and after haemodialysis (HD)

Full size image

Normetanephrine concentrations were pre-HD and post-HD elevated above the normal range (< 180 ng/l). A significant reduction of normetanephrines was detectable post-HD in comparison to pre-HD normetanephrine concentrations similarly to the metanephrines. The median decrease of normetanephrines with 56.1% was slightly higher compared to the metanephrine decrease (Fig. 3b). The percental reduction of metanephrines and normetanephrines was not significantly correlated with the percental reduction of the body weight after HD (Spearman test in bivariate correlation analysis, p = 0.887, r = −0.034, p = 0.572, r = − 0,134).

Echocardiographic analysis of left ventricular dysfunction and determination of the vena cava inferior-diameter before and after haemodialysis

The echocardiographic data sets could be analysed in 15 of 20 patients in a standardized professional setting and methods [30, 32]. Three patients were excluded due to insufficient image quality and one patient each due to unknown mitral stenosis and atrial fibrillation. An overview of the echocardiographic parameters before and after HD is shown in Additional file 1: Table S5.

Conventional parameters (Doppler echocardiography)

The maximum early-diastolic (Emax, p > 0.05), maximum late-diastolic (Amax; p < 0.05) velocity and the E/A-ratio (p < 0.05) of the mitral valve inflow were lower after HD whereas Amax and the E/A-ratio were significantly reduced after HD (Additional file 1: Table S5 and Fig. 4a). TAPSE (tricuspid annular plane systolic excursion, n = 16) and SPAP (systolic pulmonary arterial pressure, n = 13) were routinely performed for the investigation of the right ventricular function. TAPSE was not significantly different before 2.20 cm (1.5 to 3.0) and after 2.25 cm (1.6 to 3.0) HD (Wilcoxon-test, p = 0.57) but SPAP was significantly reduced from 33.01 mmHg (19.17 to 72.92, SPAP >30, n = 11) to 29.27 mmHg (14.79 to 53.43, SPAP >30, n = 6, Wilcoxon-test, p = 0.0051). Only the SPAP after HD was significantly different in patients with an UF rate less or bigger 2000 ml per session (p = 0.018) and RE less or bigger 500 ml per day (Mann-Whitney-U-test, p = 0.005). TAPSE, SPAP, copeptin, renin and aldosterone before and after HD were not significantly correlated in absolute values and in the difference values (before and after HD) in the correlation analysis (Spearman test, p > 0.05).

Fig. 4
figure 4

a E/A - ratio (early diastolic velocity of the mitral inflow/late-diastolic velocity of the mitral inflow - ratio) before and after haemodialysis (HD). b Vena cava inferior-diameter (VCID) before and after haemodialysis (HD)

Full size image

Tissue-Doppler imaging (TDI)

The maximum early-diastolic tissue velocity Vmax E’ in region of the basal inferoseptal left ventricular segment was not significantly reduced whereas the Vmax E’ in region of the basal lateral left ventricular segment was significantly reduced after HD (Additional file 1: Table S5). Significant changes in left ventricular end-diastolic pressure (E/E’ inferoseptal, E/E’ lateral) could not be observed after HD. However, values for Vmax E’ inferoseptal were lower than values for Vmax E’ lateral leading to an increased E/E’-ratio when the left ventricular pressure was estimated in region of the basal inferoseptal region of the left ventricle.

Comparison of echocardiographic parameters depending on the ultrafiltration rate and the residual excretion

Concerning the comparison of the echocardiographic parameters depending on the UF the percentage reduction of the VCID was significantly higher in patients with an UF ≥ 2000 ml (n = 8) than in patients with an UF of <2000 ml (n = 7) after HD. The other parameters did not differ depending on the UF (Additional file 1: Table S6).

The comparison of the echocardiographic parameters depending on the RE showed lower maximum early-diastolic velocity values (Emax) in patients with a RE < 500 ml (n = 8) than in patients with a RE of ≥500 ml (n = 7) before HD. The other parameters did not differ depending on the RE (Additional file 1: Table S7).

Copeptin and renin in relation to echocardiographic parameters

In addition, significant correlations between echocardiographic parameters and biochemistry parameters have been revealed before and after haemodialysis, e.g. copeptin and renin with Amax, E/E’ inferoseptal and lateral. These data are shown in Additional file 1: Table S8.

Vena cava inferior-diameter

The VCID did show ranges between 13 and 28 mm before and after HD. VCID values of less than 13 mm could be observed in two patients before HD and in seven patients after HD (Fig. 4b). Interestingly, a positive correlation between VCID before HD and patient weights before and after HD was calculated. In addition, the percentage decrease of VCID correlated to UR and other biochemistry parameters (Additional file 1: Table S9). A significant correlation between VCID and echocardiographic parameters or patient body weights has not been revealed.

Discussion

Overt or occult fluid overload is associated with higher cardiovascular mortality in CKD patients [14, 33,34,35]. Modern biomarkers for endocrine water homoeostasis, e. g. copeptin, identified in larger epidemiological studies in renal healthy subjects might be useful in the detection of fluid overload and prediction of cardiovascular mortality or outcome of sepsis (Additional file 1: Table S10) [26, 36,37,38,39,40,41,42]. Ideally, these markers should fulfill the following specifications and characteristics: i. easy accessible and no additional stress for the patient or nurses, ii. little pre-analytic effort and analyte stability, iii. no elimination by HD, iv. easy to adjust individual characteristics, e. g. residual renal excretion, gender, age, etc., and v. cost effectiveness. However, in CKD5D patients, large variability or deviation of modern peptide biomarker concentrations is related to several factors.

We have investigated the influence of residual kidney function and ultrafiltration in cardiac healthy CKD5D patients on parameters of fluid homeostasis in the vasopressin, sympathic- and the renin aldosterone system, in markers of the dilatation of the cardiac muscle and morphologic alterations in echocardiography and VCID. Copeptin is a 39-amino acid-long peptide derived from a pre-pro-hormone consisting of AVP, neurophysin II and copeptin. AVP is involved in multiple cardiovascular and renal pathways and functions. However, AVP measurements are not commonly used in clinical practice because of the biochemical features of the molecule. On the other hand, copeptin can be immunologically tested with ease and therefore be used as an AVP surrogate. Copeptin was significantly altered by the residual excretion and the ultrafiltration rate in our study but was not correlated with the renin-aldosterone system or the sympathetic nervous system. Therefore, copeptin is a new, promising reliable marker for fluid overload and cardiovascular mortality and is directly influenced by residual excretion and the ultrafiltration rate.

However, elimination by renal excretion and haemodialysis might be suspected for copeptin and individual values have to be interpreted with caution in analogy to other biomarkers [43,44,45]. It might be supposed that multiple sequential measurements focused on the individual variation could allow a prognostic value of this parameter in analogy to NT-proBNP [46]. On the other hand, classical biomarkers parameters did not correlated significantly with residual excretion or ultrafiltration in our study. Additionally, we have demonstrated no significant influence on the sympathetic nervous system and on the renin – aldosterone system.

Therefore, the ideal modern biomarker for the individual assessment of fluid overload could not be evaluated in this study which was analogue to other studies [4, 43, 45, 46]. Our study is limited to cardiac healthy patients and reflects the answer of the endocrine system and the heart function in one HD session. Therefore, future studies should also investigate other biomarkers employed in the cardiorenal syndrom, such as Cystatin C or TIMP – 2. However, a long term follow up of cardiac healthy and comprimised patients with the new biomarkers might contribute to risk management in these patients.

Interestingly, strong correlations were found with echocardiographic parameters and VCID (Additional file 1: Table S9 and S10). In general, inferoseptal E’ velocities were lower than lateral E’ velocities leading to higher inferoseptal E/E’ ratios which is analogue to former studies [32]. In addition, recent studies have shown, that in patients with normal ejection fraction lateral E/E’ have better correlations with left ventricular filling pressures, so that it could be assumed that lateral Vmax E’ and lateral E/E’ are more suitable for an echocardiographic analysis in healthy subjects. In the present study no significant differences of Vmax E’ or E/E’ obtained by measurements in the inferoseptal or lateral region could be observed. However, VCID seems to be the most suitable echocardiographic parameter for the assessment of fluid overload before and after HD.

Conclusions

In summary, this study support the notion that the value of modern biomarkers in patients with several influences on the excretion or elimination must be interpreted with caution with regards of possible fluid overload or the increased cardiovascular risk and sequential measurements might be necessary. However, standardized echocardiographic examination for the exclusion of cardiac illnesses or heart failure is the gold standard in the assessment of the fluid status and further cardiovascular risk status. Additionally, VCID is a feasible method in the hand of well-trained investigators and should be performed in all patients together with clinical data to minimize the risk for intra- or post-HD complications as hypotonic dysregulation respectively fluid overload.

Abbreviations

AVP:

Vasopressin

BMI:

Body mass index

CKD:

Chronic kidney disease

CKD5D:

End stage renal disease

CRS:

Chronic reno-cardiac syndrome

CT-proAVP:

Copeptin

EDT:

Deceleration time

HD:

Haemodialysis

Hk:

Haematocrit

KT/v:

Haemodialysis treatment adequacy

LV:

Left ventricular

MR-proANP:

Mid-regional pro-atrial natriuretic peptide

NT-proBNP:

N-terminal prohormone of brain natriuretic peptide

RE:

Residual excretion

SPAP:

Systolic pulmonary arterial pressure

TAPSE:

Tricuspid annular plane systolic excursion

TDI:

Tissue-Doppler imaging

UF:

Ultrafiltration rate

VCID:

Diameter of vena cava inferior

References

  1. Nolan CR. Strategies for improving long-term survival in patients with ESRD. J Am Soc Nephrol. 2005;16(Suppl 2):S120–7. doi:10.1681/ASN.2005060662.

    Article  PubMed  Google Scholar 

  2. Leypoldt JK, Cheung AK, Delmez JA, Gassman JJ, Levin NW, Lewis JAB, et al. Relationship between volume status and blood pressure during chronic hemodialysis. Kidney Int. 2002;61:266–75. doi:10.1046/j.1523-1755.2002.00099.x.

    Article  PubMed  Google Scholar 

  3. McCullough PA, Kellum JA, Haase M, Muller C, Damman K, Murray PT, et al. Pathophysiology of the cardiorenal syndromes: executive summary from the eleventh consensus conference of the acute dialysis quality initiative (ADQI). Contrib Nephrol. 2013;182:82–98. doi:10.1159/000349966.

    Article  PubMed  Google Scholar 

  4. Chazot C, Wabel P, Chamney P, Moissl U, Wieskotten S, Wizemann V. Importance of normohydration for the long-term survival of haemodialysis patients. Nephrol Dial Transplant. 2012;27:2404–10. doi:10.1093/ndt/gfr678.

    Article  PubMed  Google Scholar 

  5. Stewart GA, Gansevoort RT, Mark PB, Rooney E, McDonagh TA, Dargie HJ, et al. Electrocardiographic abnormalities and uremic cardiomyopathy. Kidney Int. 2005;67:217–26. doi:10.1111/j.1523-1755.2005.00072.x.

    Article  PubMed  Google Scholar 

  6. Paoletti E, Specchia C, Di Maio G, Bellino D, Damasio B, Cassottana P, et al. The worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: a 10 year survey. Nephrol Dial Transplant. 2004;19:1829–34. doi:10.1093/ndt/gfh288.

    Article  PubMed  Google Scholar 

  7. Agarwal R, Alborzi P, Satyan S, Light RP. Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial. Hypertension. 2009;53:500–7. doi:10.1161/HYPERTENSIONAHA.108.125674.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Artunc F, Nowak A, Muller C, Peter A, Heyne N, Haring H, et al. Mortality prediction using modern peptide biomarkers in hemodialysis patients--a comparative analysis. Kidney Blood Press Res. 2014;39:563–72. doi:10.1159/000368468.

    Article  CAS  PubMed  Google Scholar 

  9. Kim JS, Yang JW, Chai MH, Lee JY, Park H, Kim Y, et al. Copeptin in Hemodialysis patients with left ventricular dysfunction. Yonsei Med J. 2015;56:976–80. doi:10.3349/ymj.2015.56.4.976.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Kolonko A, Chudek J, Kujawa-Szewieczek A, Czerwienska B, Wiecek A. Serum copeptin level predicts a rapid decrease of overhydration after kidney transplantation. Clin Chem Lab Med. 2014;52:1297–303. doi:10.1515/cclm-2014-0135.

    Article  CAS  PubMed  Google Scholar 

  11. Artunc F, Nowak A, Mueller C, Breidthardt T, Twerenbold R, Wagner R, et al. Plasma concentrations of the vasoactive peptide fragments mid-regional pro-adrenomedullin, C-terminal pro-endothelin 1 and copeptin in hemodialysis patients: associated factors and prediction of mortality. PLoS One. 2014;9:e86148. doi:10.1371/journal.pone.0086148.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Ettema EM, Kuipers J, Assa S, Bakker SJL, Groen H, Westerhuis R, et al. Changes in plasma Copeptin levels during Hemodialysis: are the physiological stimuli active in Hemodialysis patients? PLoS One. 2015;10:e0127116. doi:10.1371/journal.pone.0127116.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Pellicori P, Goode KM, Nicholls R, Ahmed D, Clark AL, Cleland JG. Regional circulatory distribution of novel cardiac bio-markers and their relationships with haemodynamic measurements. Int J Cardiol. 2016;210:149-55. doi:10.1016/j.ijcard.2016.02.081.

  14. Przybylowski P, Malyszko J, Malyszko JS. Copeptin in heart transplant recipients depends on kidney function and intraventricular septal thickness. Transplant Proc. 2010;42(5):1808-11. doi:10.1016/j.transproceed.2010.03.138.

  15. Li X, Yang X, Sun Q, Chen X, Li Y. Brain natriuretic peptide and copeptin levels are associated with cardiovascular disease in patients with chronic kidney disease. Chin Med J. 2013;126:823–7.

    CAS  PubMed  Google Scholar 

  16. Mueller T, Gegenhuber A, Kronabethleitner G, Leitner I, Haltmayer M, Dieplinger B. Plasma concentrations of novel cardiac biomarkers before and after hemodialysis session. Clin Biochem. 2015;48:1163–6. doi:10.1016/j.clinbiochem.2015.07.031.

    Article  CAS  PubMed  Google Scholar 

  17. Gouya G, Sturm G, Lamina C, Zitt E, Freistatter O, Struck J, et al. The association of mid-regional pro-adrenomedullin and mid-regional pro-atrial natriuretic peptide with mortality in an incident dialysis cohort. PLoS One. 2011;6:e17803. doi:10.1371/journal.pone.0017803.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Ross BA, Wald R, Goldstein MB, Yuen DA, Leipsic J, Kiaii M, et al. Relationships Between Left Ventricular Structure and Function According to Cardiac MRI and Cardiac Biomarkers in End-Stage Renal Disease. Can J Cardiol. 2017;33(4):501-7. doi:10.1016/j.cjca.2016.11.021.

  19. Breidthardt T, Burton JO, Odudu A, Eldehni MT, Jefferies H, McIntyre CW. N-terminal pro-B-type natriuretic peptide and its correlation to haemodialysis-induced myocardial stunning. Nephron Clin Pract. 2013;123:118–22. doi:10.1159/000351190.

    Article  CAS  PubMed  Google Scholar 

  20. Franczyk B, Gluba-Brzózka A, Bartnicki P, Banach M, Rysz J. Are markers of cardiac dysfunction useful in the assessment of cardiovascular risk in dialysis patients? Curr Pharm Des. 2017; doi:10.2174/1381612823666170508152501.

  21. Fahim MA, Hayen A, Horvath AR, Dimeski G, Coburn A, Johnson DW, et al. N-terminal pro-B-type natriuretic peptide variability in stable dialysis patients. Clin J Am Soc Nephrol. 2015;10:620–9. doi:10.2215/CJN.09060914.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Corradi V, Gastaldon F, Virzì GM, Caprara C, Martino F, Ronco C. Clinical and laboratory markers of autosomal dominant polycystic kidney disease (ADPKD) progression: an overview. Minerva Med. 2015;106(1):53–64.

    CAS  PubMed  Google Scholar 

  23. Maoujoud O, Asseraji M, Aatif T, Zajjari Y, Bahadi A, Benyahya M, et al. Diagnostic value of NT-ProBNP for left ventricular hypertrophy in hemodialysis patients. Int J Artif Organs. 2013;36:419–20. doi:10.5301/ijao.5000222.

    PubMed  Google Scholar 

  24. Costanzo MR, Ronco C, Abraham WT, Agostoni P, Barasch J, Fonarow GC, et al. Extracorporeal Ultrafiltration for Fluid Overload in Heart Failure: Current Status and Prospects for Further Research. J Am Coll Cardiol. 2017;69(19):2428-45. doi:10.1016/j.jacc.2017.03.528.

  25. Nongnuch A, Panorchan K, Davenport A. Predialysis NTproBNP predicts magnitude of extracellular volume overload in haemodialysis patients. Am J Nephrol. 2014;40:251–7. doi:10.1159/000368376.

    Article  CAS  PubMed  Google Scholar 

  26. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006;52:112–9. doi:10.1373/clinchem.2005.060038.

    Article  CAS  PubMed  Google Scholar 

  27. Wahl HG, Graf S, Renz H, Fassbinder W. Elimination of the cardiac natriuretic peptides B-type natriuretic peptide (BNP) and N-terminal proBNP by hemodialysis. Clin Chem. 2004;50:1071–4. doi:10.1373/clinchem.2003.030692.

    Article  CAS  PubMed  Google Scholar 

  28. Daugirdas JT. Linear estimates of variable-volume, single-pool Kt/V: an analysis of error. Am J Kidney Dis. 1993;22:267–70.

    Article  CAS  PubMed  Google Scholar 

  29. Daugirdas JT, Depner TA. A nomogram approach to hemodialysis urea modeling. Am J Kidney Dis. 1994;23:33–40.

    Article  CAS  PubMed  Google Scholar 

  30. Hagendorff A. Transthoracic echocardiography in adult patients--a proposal for documenting a standardized investigation. Ultraschall Med. 2008;29:344–365; quiz 366-73. doi:10.1055/s-2008-1027491.

    Article  CAS  PubMed  Google Scholar 

  31. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16:233–70. doi:10.1093/ehjci/jev014.

    Article  PubMed  Google Scholar 

  32. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr. 2009;10:165–93. doi:10.1093/ejechocard/jep007.

    Article  PubMed  Google Scholar 

  33. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–34. doi:10.1056/NEJMoa1515920.

    Article  CAS  PubMed  Google Scholar 

  34. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28. doi:10.1056/NEJMoa1504720.

    Article  CAS  PubMed  Google Scholar 

  35. Fenske W, Wanner C, Allolio B, Drechsler C, Blouin K, Lilienthal J, et al. Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus. J Am Soc Nephrol. 2011;22:782–90. doi:10.1681/ASN.2010070691.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Chai SB, Hui YM, Li XM, Xiao Y, Tang CS. Plasma levels of copeptin in patients with coronary heart disease. Heart Vessel. 2009;24:79–83. doi:10.1007/s00380-008-1086-1.

    Article  Google Scholar 

  37. Jochberger S, Morgenthaler NG, Mayr VD, Luckner G, Wenzel V, Ulmer H, et al. Copeptin and arginine vasopressin concentrations in critically ill patients. J Clin Endocrinol Metab. 2006;91:4381–6. doi:10.1210/jc.2005-2830.

    Article  CAS  PubMed  Google Scholar 

  38. Katan M, Morgenthaler N, Widmer I, Puder JJ, Konig C, Muller B, et al. Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinol Lett. 2008;29:341–6.

  39. Katan M, Muller B, Christ-Crain M. Copeptin: a new and promising diagnostic and prognostic marker. Crit Care. 2008;12:117. doi:10.1186/cc6799.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Morgenthaler NG, Muller B, Struck J, Bergmann A, Redl H, Christ-Crain M. Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock. 2007;28:219–26. doi:10.1097/SHK.0b013e318033e5da.

    Article  CAS  PubMed  Google Scholar 

  41. Szinnai G, Morgenthaler NG, Berneis K, Struck J, Muller B, Keller U, et al. Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J Clin Endocrinol Metab. 2007;92:3973–8. doi:10.1210/jc.2007-0232.

    Article  CAS  PubMed  Google Scholar 

  42. Enhörning S, Hedblad B, Nilsson PM, Engström G, Melander O. Copeptin is an independent predictor of diabetic heart disease and death. Am Heart J. 2015;169(4):549-56.e1. doi:10.1016/j.ahj.2014.11.020.

  43. Bhandari SS, Loke I, Davies JE, Squire IB, Struck J, Ng LL. Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond). 2009;116:257–63. doi:10.1042/CS20080140.

    Article  CAS  Google Scholar 

  44. Voroneanu L, Covic A. Arrhythmias in hemodialysis patients. J Nephrol. 2009;22:716–25.

    CAS  PubMed  Google Scholar 

  45. Voroneanu L, Cusai C, Hogas S, Ardeleanu S, Onofriescu M, Nistor I, et al. The relationship between chronic volume overload and elevated blood pressure in hemodialysis patients: use of bioimpedance provides a different perspective from echocardiography and biomarker methodologies. Int Urol Nephrol. 2010;42:789–97. doi:10.1007/s11255-010-9767-y.

    Article  PubMed  Google Scholar 

  46. Chazot C, Vo-Van C, Zaoui E, Vanel T, Hurot JM, Lorriaux C, et al. Fluid overload correction and cardiac history influence brain natriuretic peptide evolution in incident haemodialysis patients. Nephrol Dial Transplant. 2011;26:2630–4. doi:10.1093/ndt/gfq804.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Ulrike Haagen, Global Medical Affairs- Medical Affairs Coordinator, B.R.A.H.M.S., Hennigsdorf, Germany, for the analysis of copeptin and Dr. Thomas Klemm, Labor Reising-Ackermann, Leipzig, Germany, for the excellent assistance in the pre-analytic and analytic of the specimen.

Funding

We acknowledge support from the German Research Foundation (DFG) and Leipzig University within the program of Open Access Publishing.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request at any time.

Authors’ contributions

Authors FMR, JGS and SSc participated in the data analysis, interpretation, designing, writing and revising of the manuscript. SSt, TE, SF and AH participated in the data acquisition, analysis and interpretation. Authors WGR, FB, VB and US participated in the data analysis and interpretation. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The study protocol was approved by the institutional review board, Medical Faculty of the University of Leipzig (No. 089-10-19,042,010), and informed consent was obtained from all patients.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author information

Author notes

    Authors and Affiliations

    1. Department of Internal Medicine, Neurology, Dermatology, Clinic for Endocrinology, Diabetology and Nephrology, Section of Nephrology, University Leipzig, Leipzig, Germany

      Franz Maximilian Rasche, Thomas Ebert & Silvana Feige

    2. Department of Internal Medicine, Neurology, Dermatology, Clinic for Cardiology and Angiology, University Leipzig, Leipzig, Germany

      Stephan Stoebe & Andreas Hagendorff

    3. Department of Head Medicine and Oral Health, Department of Ophthalmology, University Leipzig, Leipzig, Germany

      Wilma Gertrud Rasche

    4. Center for Geriatric Medicine at Bezirksklinikum Regensburg, Universitätsstr. 84, 93053, Regensburg, Germany

      Filip Barinka, Volker Busch & Stephan Schiekofer

    5. Institute of Clinical Immunology, Medical Faculty, University of Leipzig, Leipzig, Germany

      Ulrich Sack

    6. Translational & Experimental Medicine, Luxembourg Centre de Systems Biomedicine, Luxembourg City, Luxembourg

      Jochen G. Schneider

    7. Department of Internal Medicine II, Saarland University, Homburg Saar, Germany

      Jochen G. Schneider

    Authors
    1. Franz Maximilian Rasche
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Stephan Stoebe
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Thomas Ebert
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Silvana Feige
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Andreas Hagendorff
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Wilma Gertrud Rasche
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Filip Barinka
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Volker Busch
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. Ulrich Sack
      View author publications

      You can also search for this author in PubMed Google Scholar

    10. Jochen G. Schneider
      View author publications

      You can also search for this author in PubMed Google Scholar

    11. Stephan Schiekofer
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Stephan Schiekofer.

    Additional file

    Additional file 1: Table S1.

    Comparison of parameters depending on ultrafiltration rate (UF). Table S2. Comparison of parameters depending on residual excretion (RE). Table S3. Comparison of parameters depending on post-HD renin increase or post-HD renin decrease. Table S4. Comparison of parameters depending on post-HD aldosterone increase or post-HD aldosterone decrease. Table S5. Echocardiographic parameters before and after HD. Table S6. Echocardiographic parameters depending on the ultrafiltration rate. Table S7. Echocardiographic parameters depending on the residual excretion. Table S8. Significant correlations (Spearman-test) between echocardiographic parameters and biochemistry parameters (−: negative correlation, +: positive correlation) before and after haemodialysis (HD). Table S9. Significant correlations between biochemistry parameters and percentaged VCID decrease. Table S10. Clinical relevance of copeptin: examples of copeptin concentrations (pmol/l); mean ± SD or median (min–max). (DOCX 48 kb)

    Rights and permissions

    Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Rasche, F.M., Stoebe, S., Ebert, T. et al. Modern peptide biomarkers and echocardiography in cardiac healthy haemodialysis patients. BMC Nephrol 18, 175 (2017). https://doi.org/10.1186/s12882-017-0589-3

    Download citation

    • Received:

    • Accepted:

    • Published:

    • DOI: https://doi.org/10.1186/s12882-017-0589-3

    Keywords

    BMC Nephrology

    ISSN: 1471-2369

    Contact us